ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic Conjunctivitis

... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today announced it has submitted an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. ISTA intends to move bepotastine directly into Phase II/III clinical trials in the U.S. [click link for full article] ...